Carole Ho - 05 Aug 2025 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Reporting relationship: Chief Medical Officer
Issuer ticker: DNLI
Reported as of: 05 Aug 2025
Net transaction value: +$30,365
SEC form: 4
Accepted by SEC: 07 Aug 2025, 17:34:32 UTC
Prior SEC filing: 31 Jul 2025
Next SEC filing: 14 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Tyler Nielsen, by power of attorney

Key filing fact

Carole Ho filed Form 4 for Denali Therapeutics Inc. (DNLI) on 07 Aug 2025.

Key facts

This page summarizes Carole Ho's Form 4 filing for Denali Therapeutics Inc. (DNLI).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Aug 2025, 17:34.

Change

Previous filing in this sequence was filed on 31 Jul 2025.
Current net transaction value: +$30,365.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001724605 Primary reporting owner

Ho Carole

Relationship: Chief Medical Officer
Address: C/O DENALI THERAPEUTICS INC., 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Signature: /s/ Tyler Nielsen, by power of attorney
Signature date: 07 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNLI transaction

Common Stock

Options Exercise

Transaction value: $30,365
Shares: +44,655
Change %: +25%
Price: $0.6800
Shares after: 220,328
Date: 05 Aug 2025
Ownership: Direct
Footnotes: F1

DNLI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 183,219
Date: 05 Aug 2025
Ownership: See footnote
Footnotes: F2

DNLI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 25,000
Date: 05 Aug 2025
Ownership: See footnote
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNLI transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -44,655
Change %: -42%
Price: $0.000000
Shares after: 62,500
Date: 05 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 44,655
Exercise price: $0.6800
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Includes 134,030 Unvested RSUs.

Footnote F2

The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.

Footnote F3

The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.

Footnote F4

The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.